Coralville, IA – According to filings with the U.S. Securities and Exchange Commission, Viewpoint Molecular Targeting is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Frances Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies. Our unique theranostic agents possess properties for both diagnostic imaging and therapy for cancer, personalizing the selection of patients and optimizing patient care.

To learn more about Viewpoint Molecular Targeting, visit http://viewpointmt.com/

Contact:
Frances Johnson, Chief Executive Officer
865-356-1861

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved